All In Biotech

Drug Trial Radar · NCT05604417

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

A Phase 1 Study With a Phase 2 Expansion Cohort of Zandelisib and Tazemetostat in Relapsed or Refractory Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 2023

Primary completion

Dec 1, 2024

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Jacob Soumerai, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MEI Pharma, Inc.
First posted
Nov 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.

Conditions

  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma

Interventions

  • TAZEMETOSTATDrug

    Dosage and treatment timings per protocol

  • ZandelisibDrug

    Dosage and treatment timings per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities Phase ITime frame: Up to 28 days
  2. Complete Response Rate Phase IITime frame: up to 4 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.